Compare Eli Lilly And Co (LLY) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Microsoft — how do they compare? Eli Lilly And Co trades at $1,173.98 (market cap $1.04T), while Microsoft trades at $536.17 (market cap $3.88T). The key difference: Microsoft is far larger — about 3.7× Eli Lilly And Co's market cap, and Microsoft pays the higher dividend (0.75%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Microsoft for 142 Days on average.
| LLY | MSFT | |
|---|---|---|
Market Cap | $1.04T | $3.88T |
Volume | 3,064,878 | 19,593,392 |
Sector | Health | Technology |
52-Week High | $1.28K | $542.07 |
52-Week Low | $799.57 | $352.83 |
Typical Hold Time | 93 Days | 142 Days |
Enterprise Value | $1.09T | $3.86T |
Dividend Yield | 0.59% | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Microsoft (MSFT) trades at $534.75, up 0.94% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.74 surpassing the $4.24 expectation. Revenue grew to $281.72 billion in 2025, and net income reached $101.83 billion, reflecting a robust 40.31% net margin. Analysts maintain a strong buy consensus with an average price target of $571.76, indicating potential upside from current levels.
The outlook for Microsoft remains positive, driven by AI leadership, Azure cloud growth, and solid cash flow generation. Key opportunities include expanding AI services and cloud market share, while risks involve high capital expenditures, competitive pressures, and macroeconomic volatility. The stock's valuation multiples, such as a P/E of 29.11, are elevated but supported by earnings growth and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
